Read + Share
Hashimoto T. Editorial Comment to Enfortumab vedotin versus platinum rechallenge in
post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter
propensity score-matched study. Int J Urol 2023;30:1186-1187.
PMID: 37885321
|
 |
|
